Welcome to our dedicated page for Pulmonx Corporation news (Ticker: $LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pulmonx Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pulmonx Corporation's position in the market.
Pulmonx announced the grant of inducement awards to Mehul Joshi, the new Chief Financial Officer, consisting of a non-statutory stock option to purchase 241,409 shares of common stock and a time-based restricted stock unit award for 125,870 shares of common stock. The stock option grant has an exercise price of $9.28 per share and will vest over a three-year period, while the restricted stock units will vest over four years. The awards were approved as an inducement to Mr. Joshi's employment under Nasdaq Listing Rule 5635(c)(4).
Pulmonx (Nasdaq: LUNG) reported financial results for Q1 2024, achieving a 30% year-over-year revenue growth, recording $18.9 million in worldwide revenue, with $12.9 million in U.S. revenue. The company realized a gross margin of 75% and treated the first patient in significant clinical trials. Pulmonx appointed new executives to drive growth and expects revenue for 2024 to be in the range of $81 million to $84 million.
